False Negative Rate of C. difficile Toxins A+B EIA Test
The false negative rate of enzyme immunoassay (EIA) for C. difficile toxins A and B is approximately 25-35%, meaning EIA misses roughly one-quarter to one-third of true CDI cases.
Performance Characteristics
The sensitivity of toxin A/B EIA ranges from 27-73% depending on the specific kit and strain type, with corresponding false negative rates of 27-73% 1. In the most rigorous guideline assessment, toxin EIA demonstrated only 66.7% sensitivity compared to toxigenic culture, meaning it missed 33.3% of true positive cases 2. Another high-quality study showed toxin EIA sensitivity of 73.3% compared to PCR (false negative rate of 26.7%) 1.
Key Factors Affecting False Negative Rates:
Strain variability significantly impacts detection: Different C. difficile ribotypes produce varying toxin levels. For example, sensitivity ranges from 13.0% for ribotype AB3 to 66.7% for ribotype AB1 with certain EIA kits 3
The predominant ribotype AB17 showed 56.6% sensitivity with one commercial kit, meaning 43.4% false negatives for this common strain 3
Repeat testing does NOT meaningfully improve detection: Studies show 91% of positive EIA results occur on the first test, and the probability of a second or third test becoming positive after previous negative results is <2.5% 2
Clinical Implications
Do not rely on toxin EIA as a standalone test 2, 1. The high false negative rate means:
- Approximately 24-40% of patients with laboratory-confirmed CDI will have negative toxin EIA results 4, 5
- Negative predictive value is only 85.8-95% depending on the kit 6, 5
- Single negative EIA results cannot rule out CDI in symptomatic patients with high clinical suspicion
Recommended Approach
Use multi-step algorithms rather than standalone toxin EIA 2, 1:
- GDH screen followed by NAAT for positive results (sensitivity 91-98%, specificity 96-98%) 2
- Two-step GDH/toxin testing arbitrated by NAAT for discordant results
- Standalone NAAT (sensitivity >90%) if testing only symptomatic patients with ≥3 unformed stools in 24 hours
Critical Pitfall to Avoid
Never perform repeat testing within 7 days during the same diarrheal episode 1. The diagnostic yield is approximately 2%, and repeat testing with suboptimal specificity tests risks generating false positives. If clinical suspicion remains high despite negative testing, consider repeat testing only if symptoms worsen or clinical presentation changes significantly.
The poor sensitivity of toxin EIA has direct mortality implications, as delayed diagnosis impacts treatment decisions and infection control measures 2. Newer ultrasensitive immunoassays using single-molecule counting technology show 95-97.7% sensitivity 7, 4, but these are not yet widely available for routine clinical use.